Cell Signaling Technology Announces Alliance with Merck to Provide PhosphoScan(R) Proteomics & Antibody Development for Biomarker Discovery to Support Oncology Therapeutic Programs.DANVERS, Mass. -- Cell Signaling Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their microenvironment is the basis of development, tissue repair, and immunity as well as Technology, Inc. (CST CST abbr. 1. Central Standard Time 2. convulsive shock treatment CST Central Standard Time Noun 1. ) announced today an alliance with Merck under which it will provide its patented PhosphoScan([R]) proteomics technology for biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. and its expertise in antibody development and validation to develop high specificity biomarker biomarker /bio·mark·er/ (bi´o-mahr?ker) 1. a biological molecule used as a marker for a substance or process of interest. 2. tumor marker. bi·o·mark·er n. 1. assays to help advance Merck's targeted therapeutic programs for oncology. CST's PhosphoScan([R]) technology enables the discovery of drug target phospho-profiles (Phospho-Signatures([R])) in cells and disease tissues. PhosphoScan([R]), which involves immunoaffinity purification and mass spectroscopy mass spectroscope n. Any of various devices that use magnetic fields, electric fields, or both to determine the masses of isotopes in a sample by producing a mass spectrum. , was described in the journal Nature Biotechnology Nature Biotechnology (Nat Biotechnol; ISSN 1087-0156) is an academic journal covering the science and business of biotechnology. Nature Biotechnology is a continuation of Bio/technology (Biotechnology (NY) (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). Discoveries made with PhosphoScan[R] may provide the basis for biomarker assay development by CST, employing its expertise in antibody and immuno-assay validation. Assays developed under the alliance may be useful within Merck's drug development programs. "Our alliance with Merck represents an excellent opportunity for CST to employ its biomarker discovery and development capabilities, integrating PhosphoScan([R]) proteomics with our expertise in antibody development and validation," said Christopher Bunker, CST's Director of Business Development. "We are excited about focusing our PhosphoScan([R]) platform on Merck's targeted inhibitors to identify drug-response Phospho-Signatures([R]) that will guide the development of antibodies for use in cancer profiling studies and biomarker validation." About Cell Signaling Technology, Inc. Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST's phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development. CST's has developed and optimized procedures enabling the delivery of high value reagents, immuno-assays and contract services for research and drug development markets focused on cellular phosphorylation phosphorylation, chemical process in which a phosphate group is added to an organic molecule. In living cells phosphorylation is associated with respiration, which takes place in the cell's mitochondria, and photosynthesis, which takes place in the chloroplasts. and signaling analysis profiles. Information on CST can be obtained at the Company's website at www.cellsignal.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion